Michael Nedelcovych
Stock Analyst at TD Cowen
(1.08)
# 3,739
Out of 4,575 analysts
89
Total ratings
47%
Success rate
-1.7%
Average return
Main Sectors:
Stocks Rated by Michael Nedelcovych
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma | Maintained: Buy | $50 → $65 | $58.83 | +10.49% | 10 | Jul 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $35.94 | +11.30% | 1 | Jul 6, 2026 | |
| NVO Novo Nordisk | Maintained: Hold | $42 | $48.77 | -13.88% | 31 | Jun 29, 2026 | |
| TAK Takeda Pharmaceutical Company | Maintained: Buy | $21 | $17.24 | +21.81% | 14 | Jun 4, 2026 | |
| JNJ Johnson & Johnson | Maintained: Buy | $250 | $263.40 | -5.09% | 2 | May 29, 2026 | |
| CHRS Coherus Oncology | Maintained: Buy | n/a | $1.41 | - | 13 | May 28, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Maintained: Hold | $9.87 | $6.25 | +57.93% | 9 | Apr 30, 2026 | |
| SWX: MOLN Molecular Partners AG | Maintained: Buy | CHF 15.00 | CHF 3.18 | +371.70% | 6 | Mar 16, 2026 | |
| TYO: 4502 Takeda Pharmaceutical Company Limited | Maintained: Buy | ¥5,135 | ¥5,769 | n/a | 1 | May 21, 2025 | |
| MOLN Molecular Partners AG | Maintained: Buy | $17 | $3.89 | n/a | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | ¥6,550 | ¥2,823 | n/a | 1 | Sep 9, 2024 |
Royalty Pharma
Jul 13, 2026
Maintained: Buy
Price Target: $50 → $65
Current: $58.83
Upside: +10.49%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $35.94
Upside: +11.30%
Novo Nordisk
Jun 29, 2026
Maintained: Hold
Price Target: $42
Current: $48.77
Upside: -13.88%
Takeda Pharmaceutical Company
Jun 4, 2026
Maintained: Buy
Price Target: $21
Current: $17.24
Upside: +21.81%
Johnson & Johnson
May 29, 2026
Maintained: Buy
Price Target: $250
Current: $263.40
Upside: -5.09%
Coherus Oncology
May 28, 2026
Maintained: Buy
Price Target: n/a
Current: $1.41
Upside: -
Bausch Health Companies Inc.
Apr 30, 2026
Maintained: Hold
Price Target: $9.87
Current: $6.25
Upside: +57.93%
Molecular Partners AG
Mar 16, 2026
Maintained: Buy
Price Target: CHF 15.00
Current: CHF 3.18
Upside: +371.70%
Takeda Pharmaceutical Company Limited
May 21, 2025
Maintained: Buy
Price Target: ¥5,135
Current: ¥5,769
Upside: n/a
Molecular Partners AG
Mar 14, 2025
Maintained: Buy
Price Target: $17
Current: $3.89
Upside: n/a
Sep 9, 2024
Maintained: Buy
Price Target: ¥6,550
Current: ¥2,823
Upside: n/a